- The Vanguard Group, Inc.: Horizon Therapeutics plc

Italia Notizia Notizia

- The Vanguard Group, Inc.: Horizon Therapeutics plc
Italia Ultime Notizie,Italia Notizie
  • 📰 FN_Nachrichten
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 53%

DJ Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 08-Sep-2023 / 12:58 GMT/BST=----------------------------------------------------------------------------------------------------------------------

The Vanguard Group, Inc. Form 8.3 08-Sep-2023 / 12:58 GMT/BST =---------------------------------------------------------------------------------------------------------------------- Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION a. Full name of discloser The Vanguard Group, Inc. b.

Class of relevant security USUSD0.0001 ordinary shares Interests Short positions Number % Number % 1. Relevant securities owned and/or controlled 21,611,205 9.44% 2. Cash-settled derivatives 3. Stock-settled derivatives and agreements to purchase/ sell Total 21,611,205 9.44% All interests and all short positions should be disclosed.

Class of Product Exercising/ Exercise relevant description exercised Number of price per security e.g. call against securities unit option Other dealings 4.

Is a Supplemental Form 8 attached? No Date of disclosure 08 September 2023 Contact name Shawn Acker Telephone number 001-610-669-6713 Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:

FN_Nachrichten /  🏆 88. in DE

Italia Ultime Notizie, Italia Notizie

Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.

- The Vanguard Group, Inc.: Horizon Therapeutics plc- The Vanguard Group, Inc.: Horizon Therapeutics plcDJ Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 07-Sep-2023 / 12:59 GMT/BST=----------------------------------------------------------------------------------------------------------------------
Leggi di più »

- The Vanguard Group, Inc.: Dechra Pharmaceuticals plc- The Vanguard Group, Inc.: Dechra Pharmaceuticals plcDJ Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc 07-Sep-2023 / 12:57 GMT/BST=----------------------------------------------------------------------------------------------------------------------
Leggi di più »

Deutsche Telekom Buy (Goldman Sachs Group Inc.) 07.09.2023 | AnalyseDeutsche Telekom Buy (Goldman Sachs Group Inc.) 07.09.2023 | AnalyseDeutsche Telekom Buy (Goldman Sachs Group Inc.) 07.09.2023 | Analyse | finanzen.net
Leggi di più »

BERNSTEIN RESEARCH stuft NIKE INC auf 'Outperform'BERNSTEIN RESEARCH stuft NIKE INC auf 'Outperform'NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Nike auf 'Outperform' mit einem Kursziel von 134 US-Dollar belassen. Ihre Meinung, dass wieder anlaufende Rückzahlungen
Leggi di più »

iTeos Therapeutics Inc.: iTeos nimmt an bevorstehenden Investorenkonferenzen teiliTeos Therapeutics Inc.: iTeos nimmt an bevorstehenden Investorenkonferenzen teilWATERTOWN, Mass. und GOSSELIES, Belgien, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein im klinischen Stadium tätiges biopharmazeutisches Unternehmen, das Pionierarbeit
Leggi di più »

JEFFERIES stuft APPLE INC auf 'Buy'JEFFERIES stuft APPLE INC auf 'Buy'NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Apple in einer Produktvorschau auf 'Buy' mit einem Kursziel von 220 US-Dollar belassen. In der kommenden Woche dürfte das
Leggi di più »



Render Time: 2025-04-24 12:15:03